[{"data":1,"prerenderedAt":26},["ShallowReactive",2],{"project-e20fd67f69ef5fdf00dbae2e0701e83b":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":9,"tech_type":10,"indications":11,"official_price":12,"hospital_name":13,"hospital_names":14,"tech_company_name":13,"view_count":15,"favorite_count":16,"is_favorite":17,"approval_no":18,"approval_date":10,"regulatory_level":19,"valid_until":10,"filing_date":20,"intro":21,"detail_desc":22,"target_population":23,"compliance_list":24,"process":25},"e20fd67f69ef5fdf00dbae2e0701e83b","恶性肿瘤个性化 DC 疫苗治疗技术",[7,8],"肝癌","肺癌","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/cover/1778468106051-004恶行肿瘤个性化DC疫苗治疗技术.jpg","",[7,8],"15万/针","北京立康生命科技有限公司",[],48,1,false,"乐城第二批获批","低风险","2025年","\u003Cp>单药或联合标准治疗用于已完成切除实体瘤的术后辅助治疗；单药或联合标准治疗用于不可手术切除或未完全切除实体瘤的系统治疗。\u003C/p>\u003Cp>基于患者自身肿瘤抗原的个性化树突状细胞(DC)疫苗,激活特异性 T 细胞免疫。\u003C/p>\u003Cp>\u003Cb>适应症\u003C/b>:肝癌、肺癌等实体瘤\u003Cbr>\u003Cb>技术类型\u003C/b>:特许疫苗\u003Cbr>\u003Cb>批次\u003C/b>:乐城第二批获批\u003C/p>","基于患者自身肿瘤抗原的个性化树突状细胞(DC)疫苗,激活特异性 T 细胞免疫。",[],[],[],1779368115444]